Sodium selenate corrects glucose tolerance and heart function in STZ diabetic rats
Sodium selenate corrects glucose tolerance and heart function in STZ diabetic rats
复制标题
DOI：
10.1023/a:1006819227506
复制
发表时间：
1998-02-01
影响因子：
4.3
通讯作者：
McNeill, JH
中科院分区：
文献类型：
--
作者：
Battell, ML;Delgatty, HLM;McNeill, JH
腹腔注射亚硒酸钠可改善糖尿病大鼠的糖耐量。在链脲佐菌素糖尿病大鼠中，硒酸盐可降低喂养大鼠的血糖水平。血糖在治疗开始后3周内降至最低值。与未经治疗的糖尿病大鼠相比，接受治疗的糖尿病大鼠的食物和液体消耗减少。接受糖尿病治疗的大鼠不会因葡萄糖刺激而释放胰岛素，而对照组大鼠的胰岛素释放则明显减少。使用工作心脏装置对心脏功能的评估显示，与未治疗的糖尿病患者的心脏相比，血糖水平得到改善的糖尿病治疗组大鼠在糖尿病8周时心脏功能正常。这项研究延续了先前对亚硒酸钠体内胰岛素样作用的观察。
Sodium selenate, administered intraperitoneally (i.p.), resulted in an improvement in glucose tolerance in treated diabetic rats. Fed rat plasma glucose levels were reduced by selenate treatment in streptozotocin diabetic rats. The lowest values of blood glucose were reached within 3 weeks of beginning the treatment. Food and fluid consumption was reduced in treated compared to untreated diabetic rats. Diabetic treated rats did not release insulin in response to a glucose challenge and insulin release in response to a challenge was markedly reduced in control treated rats. Assessment of heart function using a working heart apparatus showed that treated diabetic rats with improved blood glucose levels had normal heart function at 8 weeks of diabetes in contrast to hearts from non-treated diabetics. This study extends previous observations on the in vivo insulin-like effects of sodium selenate.